MoneyWorks4Me

Lyka Labs - Quaterly Results

01 Aug 2025 Evaluate
Revenue showed a marginal decline at Rs. 291.76 millions. For the quarter ended June 2025, as compared to corresponding quarter of last year.The Net Profit of the company slipped to Rs. 8.13 millions from Rs. 17.50 millions, a decline of -53.54% on QoQ basis.The Operating Profit of the company witnessed a decrease to 40.55 millions from 46.74 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 291.76 301.05 -3.09 291.76 301.05 -3.09 1346.97 1063.96 26.60
Other Income 6.67 6.20 7.58 6.67 6.20 7.58 23.44 16.47 42.32
PBIDT 40.55 46.74 -13.24 40.55 46.74 -13.24 202.32 162.07 24.83
Interest 8.51 6.51 30.72 8.51 6.51 30.72 23.04 47.98 -51.98
PBDT 32.04 40.23 -20.36 32.04 40.23 -20.36 179.28 113.54 57.90
Depreciation 20.34 16.77 21.29 20.34 16.77 21.29 64.53 122.87 -47.48
PBT 11.70 23.46 -50.13 11.70 23.46 -50.13 114.75 -9.33 -1329.90
TAX 3.57 5.96 -40.10 3.57 5.96 -40.10 32.47 13.37 142.86
Deferred Tax 0.47 1.96 -76.02 0.47 1.96 -76.02 5.23 -2.63 -298.86
PAT 8.13 17.50 -53.54 8.13 17.50 -53.54 82.28 -22.70 -462.47
Equity 356.90 356.90 0.00 356.90 356.90 0.00 356.90 330.90 7.86
PBIDTM(%) 13.90 15.53 -10.48 13.90 15.53 -10.48 15.02 15.23 -1.39
Peers
Company Name CMP
Sun Pharma. Inds. 1850.00
Dr. Reddys Labs. 1202.70
Cipla 1399.50
Lupin 2094.45
Zydus Lifesciences 1186.05
View more..